EX-1.1 OTHERDOC 2 0002.txt JOINT FILING AGREEMENTJoint Filing Agreement • March 10th, 2003 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G/A, dated March 10, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $0.0001 per share, of Adolor Corporation is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
Exhibit A. JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated April 15, 2005 (the "Schedule 13D"), with respect to the Common Stock, par value $.001 per share, of Acadia Pharmaceutical Inc. is filed on...Joint Filing Agreement • May 2nd, 2005 • Orbimed Advisors LLC • Pharmaceutical preparations
JOINT FILING AGREEMENTJoint Filing Agreement • September 3rd, 2004 • Orbimed Advisors LLC • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on this Schedule 13G, dated August 16, 2004, (the "Schedule 13G"), with respect to the Common Stock, par value $.001 per share, of NPS Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
Exhibit 1.1 ----------- JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $0.0001 per share, of Adolor...Joint Filing Agreement • February 14th, 2003 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $0.0001 per share, of Adolor Corporation is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 26th, 2016 • Orbimed Advisors LLC • Electromedical & electrotherapeutic apparatus • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of August 22, 2016, by and among ViewRay, Inc., a Delaware corporation (the “Company”), and the investors signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
JOINT FILING AGREEMENTJoint Filing Agreement • April 9th, 2019 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13D, dated July 11, 2018 (the “Schedule 13D”), with respect to the Shares of Tricida, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
LOCK-UP AGREEMENTLock-Up Agreement • June 30th, 2020 • Orbimed Advisors LLC • Biological products, (no disgnostic substances) • New York
This LOCK-UP AGREEMENT (this “Agreement”) is made as of June 19, 2020, by and between the undersigned person or entity (the “Restricted Holder”) and Compass Therapeutics, Inc. (formerly known as Olivia Ventures, Inc.), a Delaware corporation (the “Parent”). Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Merger Agreement (as defined below).
JOINT FILING AGREEMENTJoint Filing Agreement • September 18th, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that Amendment No. 6 to Schedule 13D, dated September 12, 2023, with respect to the common stock of Galecto, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • February 21st, 2024 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that Amendment No. 6 to the Statement on Schedule 13D, dated February 16, 2024, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • March 14th, 2018 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13D, dated March 14, 2018 (the “Schedule 13D”), with respect to the Common Stock, of Corvus Pharmaceuticals, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
RELYPSA, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • December 2nd, 2013 • Orbimed Advisors LLC • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 26th day of July, 2012 (the “Effective Date”), by and among RELYPSA, INC., a Delaware corporation (the “Company”) and the investors listed on EXHIBIT A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 14th, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Common Stock, $0.0001 par value per share, of Mersana Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
Exhibit V Rollover AgreementRollover Agreement • June 20th, 2016 • Orbimed Advisors LLC • Services-testing laboratories • British Columbia
This letter agreement (this “Agreement”) sets forth the commitment of the undersigned (the “Company Securityholder”), subject to the terms and conditions contained herein, to transfer, contribute and deliver the securities of Response Biomedical Corp. (the “Company”) set forth on Schedule “A” hereto (the “Rollover Contribution Securities”) to1077801 B.C. Ltd. (the “Purchaser”) in exchange for new securities of the Purchaser provided set forth on Schedule “A” hereto and as described in the Arrangement Agreement (as defined below) (the “Purchaser Rollover Securities”).
JOINT FILING AGREEMENTJoint Filing Agreement • June 21st, 2016 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13D, dated June 21, 2016 (the “Schedule 13D”), with respect to the Ordinary Shares of Ascendis Pharma A/S is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • January 26th, 2018 • Orbimed Advisors LLC • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on this Schedule 13D, dated January 26, 2018 (the “Schedule 13D”), with respect to the Common Stock of Arsanis, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2021 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, without par value, of Xenon Pharmaceuticals Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • October 27th, 2017 • Orbimed Advisors LLC • Electromedical & electrotherapeutic apparatus
The undersigned hereby agree that the Statement on this Schedule 13D, dated October 27, 2017 (the “Schedule 13D”), with respect to the Common Stock, of ViewRay, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • August 20th, 2013 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13D, dated August 20, 2013 (the “Schedule 13D”), with respect to the common stock, par value $0.001 per share, of Supernus Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • November 1st, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that Amendment No. 2 to Schedule 13D, dated October 30, 2023, with respect to the Class A ordinary shares of Apollomics Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • November 18th, 2021 • Orbimed Advisors LLC • Surgical & medical instruments & apparatus
The undersigned hereby agree that the Statement on Schedule 13D, dated November 18, 2021, with respect to the ordinary shares of Acutus Medical, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • January 20th, 2017 • Orbimed Advisors LLC • Electromedical & electrotherapeutic apparatus • California
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of January 13, 2017, by and among the Company and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A thereto (the “Purchase Agreement”).
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2021 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Theravance Biopharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2021 • Orbimed Advisors LLC • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.00001 per share, of Krystal Biotech, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
LOCK-UP AND NO SHORTING AGREEMENTLock-Up and No Shorting Agreement • March 27th, 2017 • Orbimed Advisors LLC • Pharmaceutical preparations • New York
This LOCK-UP AND NO SHORTING AGREEMENT (this “Agreement”) is made as of March __, 2017, by and between the undersigned person or entity (the “Restricted Holder”) and Aerpio Pharmaceuticals, Inc. (formerly known as Zeta Acquisition Corp. II), a Delaware corporation (the “Parent”). Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Merger Agreement (as defined below).
JOINT FILING AGREEMENTJoint Filing Agreement • April 12th, 2018 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13D, dated April 12, 2018 (the “Schedule 13D”), with respect to the Shares of Synlogic, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • March 29th, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on Schedule 13D, dated March 27, 2023 with respect to the common stock of Terns Pharmaceuticals, Inc, is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • April 15th, 2021 • Orbimed Advisors LLC • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on Schedule 13D, dated April 14, 2021, with respect to the ordinary shares of Ikena Oncology, Inc., is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • November 12th, 2013 • Orbimed Advisors LLC • Electromedical & electrotherapeutic apparatus
The undersigned hereby agree that the Statement on this Schedule 13D, dated November 12, 2013 (the “Schedule 13D”), with respect to the common stock, $0.001 par value per share, of NxStage Medical, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
Exhibit S Form of Voting and Support AgreementOrbimed Advisors LLC • June 20th, 2016 • Services-testing laboratories
As you know, OrbiMed Advisors LLC and Shanghai Runda Medical Technology Co., Ltd., through 1077801 B.C. Ltd. (the “Purchaser”) have been in discussions with the board of directors of Response Biomedical Corp. (“Response”) regarding a proposed transaction (the “Proposed Transaction”) to acquire all of the issued and outstanding shares in the capital of Response. It is contemplated that the Proposed Transaction will be implemented by way of a plan of arrangement under the Business Corporations Act (British Columbia), the details of which are set forth in a definitive arrangement agreement (the “Arrangement Agreement”), a draft of which has been provided to you and which is to be entered into by the Purchaser and Response upon the execution and delivery by you of this agreement. The execution and delivery of this agreement by you is a condition to the entering into of the Arrangement Agreement.
JOINT FILING AGREEMENTJoint Filing Agreement • July 28th, 2016 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13D, dated July 28, 2016 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • March 24th, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that this Amendment No. 3 to Schedule 13D, dated March 22, 2023, with respect to the common stock of CalciMedica, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
AGREEMENTAgreement • June 6th, 2005 • Orbimed Advisors LLC • Pharmaceutical preparations • California
This Agreement, dated as of May 27, 2005 (this “Agreement”), by and among Caduceus Capital Master Fund Limited, Caduceus Capital II, L.P., OrbiMed Advisors LLC (“OrbiMed Advisors”) and OrbiMed Capital LLC (collectively, along with their respective Associates and Affiliates, as hereinafter defined, the “Caduceus Group”), and BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), sets forth the parties’ agreement with respect to the nominees for director at the Company’s 2005 Annual Meeting of Stockholders (the “Annual Meeting”) and various other matters related thereto and described below.
JOINT FILING AGREEMENTJoint Filing Agreement • March 6th, 2018 • Orbimed Advisors LLC • Electromedical & electrotherapeutic apparatus
The undersigned hereby agree that the Statement on this Schedule 13D, dated March 6, 2018 (the “Schedule 13D”), with respect to the Common Stock, of ViewRay, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • August 26th, 2022 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on Schedule 13D, dated August 24, 2022, with respect to the ordinary shares of Arcutis Biotherapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • August 11th, 2023 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that Amendment No. 1 to the Statement on Schedule 13D, dated August 10, 2023, with respect to the ordinary shares and American depository shares of Gracell Biotechnologies Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
